Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
XmAb18087 · 1 trial · 2 indications
Treatment-related adverse events as assessed by CTCAE v4.03
Establishing a safe and tolerable dose of XmAb18087 administered by intravenous (IV) dosing in NET and GIST patients
| Arm | Type | Description |
|---|---|---|
| XmAb18087 | EXPERIMENTAL | XmAb18087 administered on days 1, 8, 15, and 22 of each 28-day cycle for a total of 3 cycles |
| Name | Type | Description |
|---|---|---|
| XmAb18087 | BIOLOGICAL | monoclonal bispecific antibody |
Inclusion Criteria: * Histologically or cytologically confirmed well differentiated low or intermediate grade (World Health Organization \[WHO\] Grade 1 or 2) NET of pancreatic, gastrointestinal, lung, or undetermined origin that is locally advanced or metastatic and has progressed within the past ...
XmAb18087 is an investigational monoclonal antibody being studied for the treatment of neuroendocrine tumors and gastrointestinal stromal tumors. It is currently in Phase 1 clinical development for these indications, with a completed trial that enrolled 62 patients.
XmAb18087 is being developed by Xencor, Inc., a biopharmaceutical company traded on the Nasdaq under the ticker symbol XNCR. The company is conducting clinical research on this antibody for oncology indications.
XmAb18087 is in Phase 1 clinical development. A Phase 1 study of the drug has been completed, and it remains an investigational agent. It has not been approved by regulatory authorities for any use.
XmAb18087 has been studied in a Phase 1 clinical trial with the identifier NCT03411915. This completed trial enrolled 62 participants with neuroendocrine tumors and gastrointestinal neoplasms, and it was conducted in the United States.
XmAb18087 is the drug name used in clinical research. No alternative names have been established for this investigational monoclonal antibody. It is identified by its compound name in the clinical trial registry.